Evidence map›Paper›PMID 40740764›Full record

ArticleFrontiers in immunology2025

Oligosaccharides from the seeds of

Ben Liu, Jiayi Jin, Yuming Zhou, Zhipeng Shang, Peng Meng, Maoru Du, Feng Geng, Xue Gao, Feng Zhao, Zhenguo Su and 1 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Immunomodulatory Effects ofBiomolecules · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ben Liu *School of Pharmacy, Binzhou Medical University, Yantai, China.
Jiayi Jin *School of Pharmacy, Binzhou Medical University, Yantai, China.
Yuming Zhou *Department of Laboratory Medicine, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China.
Zhipeng ShangSchool of Pharmacy, Binzhou Medical University, Yantai, China.
Peng MengYantai Hospital of Traditional Chinese Medicine, Binzhou Medical University, Yantai, China.
Maoru DuSchool of Pharmacy, Binzhou Medical University, Yantai, China.
Feng GengSchool of Pharmacy, Binzhou Medical University, Yantai, China.
Xue GaoSchool of Pharmacy, Binzhou Medical University, Yantai, China.
Feng ZhaoSchool of Pharmacy, Binzhou Medical University, Yantai, China.
Zhenguo SuDepartment of Laboratory Medicine, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China.
Xiaohong PanSchool of Pharmacy, Binzhou Medical University, Yantai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Methods: Crude oligosaccharides were purified to yield mixture SRSV (86% sugar content), comprising sucrose, raffinose, stachyose, and verbascose (mass ratio 19:16.8:50:14.2). Immunosuppressed mice (CTX-induced) were treated with SRSV (150 mg/kg). Gut microbiota (GM) diversity was analyzed via 16S rRNA sequencing, and serum metabolites were profiled using metabolomics. GM-depleted mice (antibiotic-treated) and L-arginine supplementation experiments were used for mechanistic validation. Results: SRSV preserved intestinal villi integrity, reversed CTX-induced immune organ atrophy, and restored the CD4+T/CD8+T ratio. It enhanced bone marrow hematopoiesis, elevated peripheral white blood cell and lymphocyte counts, and modulated serum TNF-α levels. SRSV increased GM diversity, enriching beneficial taxa (e.g., Discussion: SRSV attenuates CTX-induced immunosuppression through GM-dependent mechanisms and L-arginine-mediated immunomodulation. GM integrity is essential for SRSV efficacy, as its depletion abolishes protection. The restitution of L-arginine levels underpins SRSV's capacity to restore immune homeostasis. Conclusion: SRSV from

Indexed as

ArginineCyclophosphamideFabaceaeGastrointestinal MicrobiomeImmune ToleranceOligosaccharidesSeedsAnimalsImmunosuppression TherapyImmunosuppressive AgentsMaleMiceArginineCyclophosphamideImmunosuppressive AgentsOligosaccharideschemotherapyDolichos lablab L.gut microbiomeimmunosuppressionoligosaccharideprebiotics

Identifiers

PMID40740764
PMCPMC12307210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.